Abstract
Hematopoietic stem cell (HSC) gene therapy has effectively become a therapeutic option largely due to the resounding clinical successes in patients with primary immunodeficiencies (PIDs) such as X-linked severe immunodeficiency (SCID-X1), adenosine deaminase deficiency (ADA-SCID), Wiskott-Aldrich syndrome (WAS), and chronic granulomatous disease (CGD). HSC gene therapy is also being investigated in patients with metabolic diseases such as X-linked adrenoleukodystrophy (ALD) and metachromatic leukodystrophy (MLD) and inherited blood disorders such as β-thalassemia and sickle cell disease (SCD) where some therapeutic benefits have been reported more recently. Safer and more efficient self-inactivating (SIN) γ-retroviral and lentiviral vectors have been developed to overcome the genotoxicity imparted by γ-retroviral vectors with intact long terminal repeat (LTR). The discovery and maturation of gene-editing platforms, including zinc-finger nuclease (ZFN), transcription activator-like effector nucleases (TALEN), and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9, offer exciting prospective strategies for further improving gene therapy by targeting the repair of diseased genes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.